ADA 2019: Dapagliflozin Treatment for 24 Weeks Improved CV Risk Factors in Patients With Inadequately Controlled Type 2 Diabetes
The efficacy of an SGLT2 inhibitor and DPP-4 inhibitor in preventing CV disease was compared.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.